All Stories

  1. Cell-specific epigenome-wide DNA methylation in peripheral CD4(+) lymphocytes from patients with primary biliary cholangitis
  2. Joint Tissues: Convergence and Divergence of the Pathogenetic Mechanisms of Rheumatoid Arthritis and Osteoarthritis
  3. Evaluation of a Gel Loaded With M101 on Bone and Peri‐Implantitis Healing: An Experimental In Vivo Study
  4. Urinary soluble CD163 is useful to predict lupus nephritis activity and to monitor standard-of-care therapy response
  5. Common Toll-like receptor 7 variants define disease risk and phenotypes in juvenile-onset systemic lupus erythematosus
  6. Across ancestries, HLA-B∗08:01∼DRB1∗03:01 (DR3) and HLA-DQA∗01:02 (DR2) increase the risk to develop juvenile-onset systemic lupus erythematosus through low complement C4 levels
  7. Interferon-γ release assay as an emergent powerful biomarker in systemic lupus erythematosus
  8. Triggering role of some environmental and individual factors in provoking rheumatoid arthritis and joint symptoms at preclinical stages of the disease
  9. Urinary soluble CD163 is useful as “liquid biopsy” marker in lupus nephritis at both diagnosis and follow-up to predict impending flares
  10. Quantification of C1 inhibitor activity using a chromogenic automated assay: analytical and clinical performances
  11. Editorial from the new editor-in-chief
  12. At Early Rheumatoid Arthritis Stage, the Infectious Spectrum Is Driven by Non-Familial Factors and Anti-CCP Immunization
  13. Blocking Orai1 constitutive activity inhibits B-cell cancer migration and synergistically acts with drugs to reduce B-CLL cell survival
  14. Type I interferon associated epistasis may contribute to early disease-onset and high disease activity in juvenile-onset lupus
  15. Not just another klass (JAK) of inhibitors for allergies
  16. Orai1 Ca2+ channel modulators as therapeutic tools for treating cancer: Emerging evidence!
  17. Blocking Orai1 constitutive activity inhibits B-cell cancer migration and synergistically acts with drugs to reduce B-CLL cell survival
  18. Low performance of interferon gamma release assay Quantiferon-TB gold coupled or not with Pst1/3/lipoglycan humoral detection to predict Mycobacterium tuberculosis complex disease in a low-burden area
  19. Impact of imlifidase treatment on immunoglobulins in an HLA-hypersensitized lupus nephritis patient with anti-SSA/SSB antibodies after kidney transplantation: A case report
  20. Predictive risk factors before the onset of familial rheumatoid arthritis: the Tatarstan cohort study
  21. Lupus Nephritis Risk Factors and Biomarkers: An Update
  22. Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases
  23. JAK inhibition for CD3− CD4+ lymphocytic-variant hypereosinophilic syndrome
  24. Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database
  25. Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus
  26. Immunological and translational key challenges in systemic lupus erythematosus: A symposium update
  27. Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission
  28. Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases
  29. Anti-Citrullinated Peptide Antibodies Control Oral Porphyromonas and Aggregatibacter species in Patients with Rheumatoid Arthritis
  30. Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study
  31. The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation
  32. Editorial: Epigenetic aspects of autoimmune diseases
  33. Kappa-index: Real-life evaluation of a new tool for multiple sclerosis diagnosis
  34. Myositis-specific autoantibodies in clinical practice: Improving the performance of the immunodot
  35. Interplay of Environmental, Individual and Genetic Factors in Rheumatoid Arthritis Provocation
  36. Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study
  37. Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response
  38. Possible mechanism of the implementing the trigger role of air pollution in rheumatoid arthritis (preliminary data)
  39. Long non-coding RNA Xist contribution in systemic lupus erythematosus and rheumatoid arthritis
  40. Altered DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis
  41. Lupus band test can be used in combination with anti-chromatin antibodies and complement analysis to predict transition from cutaneous to systemic lupus
  42. Provocation of oxidative stress by heavy metals as a possible trigger factor in the development of rheumatoid arthritis
  43. SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases
  44. Editorial: Role of Macrophage MicroRNAs in Inflammatory Diseases and Cancer
  45. Combining multi-antigenic immunodot with indirect immunofluorescence on HEp-2 cells improves the diagnosis of systemic sclerosis
  46. Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia
  47. A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases
  48. Altered DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis
  49. Tocilizumab controls bone turnover in early polymyalgia rheumatica
  50. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases
  51. Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade
  52. An elevated polyclonal free light chain level reflects a strong interferon signature in patients with systemic autoimmune diseases
  53. Causal risk and protective factors in rheumatoid arthritis: A genetic update
  54. Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases
  55. CD5 and B lymphocyte responses: multifaceted effects through multitudes of pathways and channels
  56. Évaluation de la taille des glandes salivaires majeures dans le syndrome de Gougerot-Sjögren primitif : comparaison de l’examen clinique et de l’échographie
  57. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases
  58. Epigenetics in Primary Sjögren’s Syndrome
  59. Linking genetic variation with epigenetic profiles in Sjögren's syndrome
  60. JAK Inhibitors and Oxidative Stress Control
  61. Assessment of major salivary gland size in primary Sjögren's syndrome: Comparison between clinical examination and ultrasonography
  62. Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren’s Syndrome and Primary Biliary Cholangitis
  63. News and meta-analysis regarding anti-Beta 2 glycoprotein I antibodies and their determination
  64. Innate B Cells: the Archetype of Protective Immune Cells
  65. JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren’s Syndrome
  66. The Innate Part of the Adaptive Immune System
  67. Complement System: a Neglected Pathway in Immunotherapy
  68. Toll-Like Receptors, Infections, and Rheumatoid Arthritis
  69. STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia
  70. Editorial: Shaping of Human Immune System and Metabolic Processes by Viruses and Microorganisms
  71. Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives
  72. Psychological stress and rheumatoid arthritis – interference of pathogenetic mechanisms
  73. In seroconverted rheumatoid arthritis patients a multi-reactive anti-herpes IgM profile is associated with disease activity
  74. Peripheral-blood b-cell subset disturbances in inflammatory joint diseases induced by Tropheryma whipplei
  75. Rapid and complete response to idelalisib in a case of Richter syndrome
  76. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
  77. A Pathogenic Cytokine Network Is Associated with Pro-Inflammatory B Cells in Systemic Lupus Erythematosus Patients
  78. Microbiota analysis in rheumatoid arthritis: News and perspectives
  79. The regulatory capacity of B cells directs the aggressiveness of CLL
  80. Prevalence and Incidence of Upper Respiratory Tract Infection Events Are Elevated Prior to the Development of Rheumatoid Arthritis in First-Degree Relatives
  81. Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies
  82. Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy
  83. Épigénome et syndrome de Gougerot-Sjögren
  84. DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag
  85. Clinical Characteristics of Pruritus in Systemic Sclerosis Vary According to the Autoimmune Subtype
  86. Associations between Viral Infection History Symptoms, Granulocyte Reactive Oxygen Species Activity, and Active Rheumatoid Arthritis Disease in Untreated Women at Onset: Results from a Longitudinal Cohort Study of Tatarstan Women
  87. Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren’s syndrome
  88. Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion
  89. Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia
  90. Constitutive calcium entry and cancer: updated views and insights
  91. Calcium Signaling: From Normal B Cell Development to Tolerance Breakdown and Autoimmunity.
  92. Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus
  93. Immunophenotyping As a New Tool for Classification and Monitoring of Systemic Autoimmune Diseases
  94. Memory B Cells and Response to Abatacept in Rheumatoid Arthritis
  95. Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity
  96. Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica
  97. Molecular Dynamics Simulations of Membrane-Bound STIM1 to Investigate Conformational Changes during STIM1 Activation upon Calcium Release
  98. Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome
  99. Isolated Cardiac Richter Syndrome: a Case Report
  100. DNA methylation signatures in Sjögren syndrome
  101. How Rheumatoid Arthritis Can Result from Provocation of the Immune System by Microorganisms and Viruses
  102. CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes
  103. Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up
  104. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises
  105. Defective DNA methylation in salivary gland epithelial acini from patients with Sjögren's syndrome is associated with SSB gene expression, anti-SSB/LA detection, and lymphocyte infiltration
  106. Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia
  107. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study
  108. B lymphocytes of chronic lymphocytic leukemia, regulatory B lymphocytes which ignore?
  109. Abatacept efficacy in rheumatoid arthritis is dependent upon baseline blood B-cell levels
  110. An in silico Approach Reveals Associations between Genetic and Epigenetic Factors within Regulatory Elements in B Cells from Primary Sjögren’s Syndrome Patients
  111. Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis
  112. AB0305 Pre-Treatment B-Cell Lymphopenia is Associated with a Low Response Rate to Abatacept in Patients with Rheumatoid Arthritis
  113. Au-delà de nos gènes: la révolution de l’épigénétique
  114. FRI0280 Efficacy and Safety of Tocilizumab as First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study (Tenor)
  115. FRI0404 Disturbances of T and B Cell Homeostasis Characterized Primary Antiphospholipid Patients During their Follow-Up of Venous Thromboembolism
  116. Épigénétique et médecine prédictive
  117. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion
  118. Genetics and Epigenetics of Autoimmune Diseases
  119. Human Endogenous Retrovirus Group E and Its Involvement in Diseases
  120. Epigenetics and autoimmune diseases: the X chromosome-nucleolus nexus
  121. A1.9 Among patients with venous thrombo-embolism, B cell subset disturbances characterise those with primary antiphospholipid syndrome
  122. A7.15 B-cell lymphopenia is associated with a low response rate to abatacept in patients with rheumatoid arthritis
  123. Annexin A2 autoantibodies in thrombosis and autoimmune diseases
  124. Calcium signaling and cell fate: how can Ca2+ signals contribute to wrong decisions for Chronic Lymphocytic Leukemic B lymphocyte outcome?
  125. Endothelial Cell Autoreactivity and Infection
  126. How the Environment Influences Epigenetics, DNA Methylation, and Autoimmune Diseases
  127. Génomique, épigénétique et pathologies
  128. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis
  129. The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review
  130. Salivary gland ultrasonography improves the diagnostic performance of the 2012 American College of Rheumatology classification criteria for Sjogren's syndrome
  131. The contribution of epigenetics in Sjögren’s Syndrome
  132. Diagnostic criteria for autoimmune neutropenia
  133. B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody–mediated rejection
  134. B1- and CD5-Positive B Cells
  135. A8.31 Characterisation of human transitional B-cells though their regulatory functions
  136. Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren’s syndrome
  137. Glomerular Basement Membrane Autoantibodies
  138. Level of agreement between 2002 American–European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren’s syndrome and reasons for discrepancies
  139. Lymphocytotoxic Autoantibodies
  140. Épigénétique et auto-immunité
  141. DNA methylation modulates HRES1/p28 expression in B cells from patients with Lupus
  142. MicroRNAs and multiple sclerosis: from physiopathology toward therapy
  143. B-Lymphocyte Signalling Abnormalities and Lupus Immunopathology
  144. Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets
  145. Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab)
  146. Epigenetic dysregulation in salivary glands from patients with primary Sjögren's syndrome may be ascribed to infiltrating B cells
  147. A5.1 Abnormal Calcium Influx in T and B Lymphocytes from Systemic Lupus Erythematosus Patients is Related to STIM-1 Over-Expression
  148. A7.8 DNA Demethylation in Salivary Gland Epithelial Cells from Patients with Primary Sjögren’s Syndrome may be Ascribed to Infiltrating B Cells
  149. Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis
  150. Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden
  151. La présence d’anticorps anti-cellules HEK-293T caractérise les patients porteurs d’une glomérulonéphrite lupique active
  152. Altered patterns of epigenetic changes in systemic lupus erythematosus and auto-antibody production: Is there a link?
  153. CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte
  154. Pierre Youinou: When intuition and determination meet autoimmunity
  155. Epigenetics and Sjogren’s Syndrome
  156. Mesangial Cell-Specific Antibodies Are Central to the Pathogenesis of Lupus Nephritis
  157. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy
  158. Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1
  159. Les auto-anticorps adoptent maintes combinaisons au cours de l’hépatite auto-immune…
  160. Epigenetic alterations and autoimmune disease
  161. Intérêt des anticorps anti-prothrombine et des anticorps anti-phosphatidylsérine/prothrombine dans le bilan d’une thrombose
  162. Quel est l’intérêt de la recherche des anticorps anti-nucléolaires dans la sclérodermie systémique ?
  163. Quels auto-anticorps pour le diagnostic et le suivi de la néphropathie lupique ?
  164. Auto-anticorps anti-membrane basale glomérulaire et syndrome de Goodpasture
  165. CD5 Promotes IL-10 Production in Chronic Lymphocytic Leukemia B Cells through STAT3 and NFAT2 Activation
  166. Les ANCA (typiques ou non) en pratique médicale courante
  167. CD5 Expression in B Cells from Patients with Systemic Lupus Erythematosus
  168. DNA Methylation and B-Cell Autoreactivity
  169. Epigenetics and Autoimmunity, with Special Emphasis on Methylation
  170. Aberrant expression of CD6 on B-cell subsets from patients with Sjögren’s syndrome
  171. Epigenetics in autoimmune disorders: Highlights of the 10th Sjögren's Syndrome Symposium
  172. The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome
  173. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes
  174. Epigenetics and autoimmunity
  175. Glomerular Antibodies in Lupus Nephritis
  176. Pharmacological role and clinical applications of interleukin-6 in rheumatoid disease
  177. 1093 ANTI-α ACTININ ANTIBODIES ARE INDEPENDENT PREDICTORS OF RESPONSE TO TREATMENT IN AUTOIMMUNE HEPATITIS TYPE 1
  178. Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies
  179. Endogenous retrovirus control is impaired in B cells from patients with systemic lupus erythematosus
  180. NFAT2 and STAT3 control type 2 cytokines in CD5 B cells
  181. Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases
  182. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis
  183. Conference Scene: Updating the Highlights of SjöGren‘s Syndrome
  184. Intérêt de la TEP au FDG dans les lymphomes folliculaires
  185. Monoclonal anti-CD20 antibodies: Mechanisms of action and monitoring of biological effects
  186. Mécanismes de l’action des anticorps monoclonaux anti-CD20 et surveillance biologique de leurs effets
  187. IL-10 Production by B Cells Expressing CD5 with the Alternative Exon 1B
  188. New ELISA for B Cell-Activating Factor
  189. Autoreactive B Cells and Epigenetics
  190. The Revolution of Epigenetics in the Field of Autoimmunity
  191. B lymphocyte cytokines and rheumatic autoimmune disease
  192. Which autoantibodies announce that lupus nephritis is on the way?
  193. IL-6 Modulates CD5 Expression in B Cells from Patients with Lupus by Regulating DNA Methylation
  194. Les maladies inflammatoires chroniques de l’intestin : quels autoanticorps choisir ?
  195. Purine-Rich Box-1-Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells
  196. Selection of the Alternative Exon 1 from the cd5 Gene Down-Regulates Membrane Level of the Protein in B Lymphocytes
  197. Intérêt des nouveaux examens sérologiques pour la néphropathie lupique
  198. Anti-α-Actinin Antibodies Cross-react with Anti-ssDNA Antibodies in Active Autoimmune Hepatitis
  199. Renal Involvement in Wegener’s Granulomatosis
  200. The paradox of CD5-expressing B cells in systemic lupus erythematosus
  201. Anticorps anti-C1q et anticorps anti-α-actinine: nouveaux marqueurs de la glomérulonéphrite lupique
  202. Anti-alpha-actinin antibodies: A new marker of lupus nephritis
  203. Anticorps anti-α-actinine et anticorps anti-C1q: deux nouveaux «marqueurs» pour la glomérulonéphrite lupique
  204. Apport des nouveaux examens biologiques au diagnostic de la polyarthrite rhumatoïde
  205. CD5 links humoral autoimmunity with B-cell chronic lymphocytic leukemia
  206. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB-TREATED patients with Sjögren's syndrome
  207. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20)
  208. LYMPHOCYTOTOXIC AUTOANTIBODIES
  209. Les anticorps anti-ADN ne sont plus ce qu'ils étaient!… L'apport des nouvelles techniques de dépistag e au diagnostic du lupus érythémateux disséminé
  210. Les nouveaux ANCA : leur mode d'emploi
  211. Double Reactivity Against Actin and α-Actinin Defines a Severe Form of Autoimmune Hepatitis Type 1
  212. Le pourquoi et le commentde l'auto-immunité
  213. Les nouveaux autoanticorps du syndrome de Gougerot-Sjögren primaire
  214. B lymphocytes on the front line of autoimmunity
  215. Endothelium, a target for immune-mediated assault in connective tissue disease
  216. Association of α-actinin–binding anti–double-stranded DNA antibodies with lupus nephritis
  217. An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes
  218. Characterization of the human CD5 endogenous retrovirus-E in B lymphocytes
  219. B Lymphocytes Are Required for Development and Treatment of Autoimmune Diseases
  220. The Anti-Alpha-Actinin Test Completes Anti-DNA Determination in Systemic Lupus Erythematosus
  221. B Cell Response to Surface IgM Cross-Linking Identifies Different Prognostic Groups of B-Chronic Lymphocytic Leukemia Patients
  222. Rheumatoid factor on a daily basis
  223. Role of B-cell antigen receptor-associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells
  224. Les lymphocytes B réhabilités : leur rôle est déterminant dans la genèse de l'auto-immunité
  225. Dysfunctional B cells in systemic lupus erythematosus
  226. Requirement for B lymphocytes in autoimmunity development
  227. Apport des examens sérologiques au diagnostic de la polyarthrite rhumatoïde : les leçons du suivi de 270 malades pendant trois ans
  228. The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases
  229. Effects of Anti-Endothelial Cell Antibodies in Leprosy and Malaria
  230. CD5-Expressing B Cells and Infection
  231. CD5-Expressing B Cells and Infection
  232. Endothelial Cell Autoreactivity and Infection
  233. Endothelial Cell Autoreactivity and Infection
  234. Recurrence of ANCA-positive glomerulonephritis immediately after renal transplantation
  235. Antiendothelial cell antibodies in systemic lupus erythematosus
  236. Autoantibodies to heparan sulfate proteoglycans
  237. Consequences of Fcγ receptor type III reactivity in non-organ-specific autoimmune diseases
  238. Pathogenic effects of anti-Fc gamma receptor IIIb (CD16) on polymorphonuclear neutrophils in non-organ-specific autoimmune diseases
  239. Cross-Linking of Human Fc RIIIb Induces the Production of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor by Polymorphonuclear Neutrophils
  240. Recent Progress in the Understanding of B-Cell Functions in Autoimmunity
  241. Autoanticorps contre les polynucléaires neutrophiles au cours des maladies auto-immunes systémiques
  242. Functional heterogeneity of anti-endothelial cell antibodies
  243. Anti-Endothelial Cell Antibodies (AECA) in Systemic Sclerosis - Increased Sensitivity using Different Endothelial Cell Substrates and Association with Other Autoantibodies
  244. Characterization of murine monoclonal anti-endothelial cell antibodies (AECA) produced by idiotypic manipulation with human AECA
  245. Two populations of endothelial cell antibodies cross-react with heparin